In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

When compared to published data with inclisiran, a small interfering RNA (siRNA) molecule that inhibits production of the ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine hairpins, they increased cholesterol uptake by cells and reduced ...

NEW ORLEANS -- Innovations in lipid lowering get a major chance to shine, and potentially move the needle in cardiometabolic ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...

Please provide your email address to receive an email when new articles are posted on . Topline results from two phase 3 trials of a novel oral PCSK9 inhibitor for treatment of HeFH and hyperlipidemia ...